Zirabev was approved for medical use in the United States in June 2019, and in Australia in November 2019.In June 2020, Mvasi was approved for medical use in Australia.In August 2020, Aybintio was approved for use in the European Union.In September 2020, Equidacent was approved for use in the European Union.On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Alymsys, intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix. Alymsys was approved for medical use in the European Union in March 2021.In January 2021, Onbevzi was approved for medical use in the European Union.In June 2019, and June 2021, Zirabev was approved for medical use in Canada.Abevmy was approved for medical use in the European Union in April 2021, and in Australia in September 2021.In September 2021, Bambevi was approved for medical use in Canada.Bevacip and Bevaciptin were approved for medical use in Australia in November 2021.In November 2021, Abevmy and Aybintio were approved for medical use in Canada.In April 2022, Alymsys was approved for medical use in the United States.In September 2022, Vegzelma was approved for medical use in the United States.
The committee concluded that breast cancer clinical studies of patients taking Avastin have shown no advantage in survival rates, no improvement in quality of life, and significant side effects.On 11 October 2011, the U.S. Food and Drug Administration (FDA) announced that the agency was revoking the agencys approval of the breast cancer indication for bevacizumab after concluding that the drug had not been shown to be safe and effective for that use.In the EU, bevacizumab in combination with paclitaxel is indicated for first-line treatment of adults with metastatic breast cancer. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adults with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Renal cancers
In certain renal (kidney) cancers, bevacizumab improves the progression free survival time but not survival time. In 2009, the FDA approved bevacizumab for use in metastatic renal cell cancer (a form of kidney cancer). following earlier reports of activity EU approval was granted in 2007.In the EU, bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adults with advanced and/or metastatic renal cell cancer. Brain cancers
Bevacizumab slows tumor growth but does not affect overall survival in people with glioblastoma multiforme. The FDA granted accelerated approval for the treatment of recurrent glioblastoma multiforme in May 2009. A 2018 Cochrane review deemed there to not be good evidence for its use in recurrences either.